CN109475543A - 用磷酸酶抑制剂治疗骨髓发育不良综合征的临床方案 - Google Patents

用磷酸酶抑制剂治疗骨髓发育不良综合征的临床方案 Download PDF

Info

Publication number
CN109475543A
CN109475543A CN201780019895.5A CN201780019895A CN109475543A CN 109475543 A CN109475543 A CN 109475543A CN 201780019895 A CN201780019895 A CN 201780019895A CN 109475543 A CN109475543 A CN 109475543A
Authority
CN
China
Prior art keywords
compound
day
method described
amount
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780019895.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·F·利斯特
D·A·塞尔曼
J·S·科瓦奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lee Moffitt Cancer Center and Research Institute Inc
Lixte Biotechnology Inc
Original Assignee
H Lee Moffitt Cancer Center and Research Institute Inc
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center and Research Institute Inc, Lixte Biotechnology Inc filed Critical H Lee Moffitt Cancer Center and Research Institute Inc
Publication of CN109475543A publication Critical patent/CN109475543A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780019895.5A 2016-01-27 2017-01-27 用磷酸酶抑制剂治疗骨髓发育不良综合征的临床方案 Pending CN109475543A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287858P 2016-01-27 2016-01-27
US62/287,858 2016-01-27
PCT/US2017/015237 WO2017132445A1 (en) 2016-01-27 2017-01-27 Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor

Publications (1)

Publication Number Publication Date
CN109475543A true CN109475543A (zh) 2019-03-15

Family

ID=59398691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780019895.5A Pending CN109475543A (zh) 2016-01-27 2017-01-27 用磷酸酶抑制剂治疗骨髓发育不良综合征的临床方案

Country Status (6)

Country Link
US (2) US20190111053A1 (https=)
EP (1) EP3407887B1 (https=)
JP (1) JP6964593B2 (https=)
CN (1) CN109475543A (https=)
CA (1) CA3051828A1 (https=)
WO (1) WO2017132445A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
DK3294287T3 (da) 2015-05-15 2020-06-08 Lixte Biotechnology Inc Oxabicycloheptan-prodrugs
US20190240290A1 (en) * 2016-08-04 2019-08-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Companion diagnostic for combination lenalidomide and erythropoietin treatment
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150045373A1 (en) * 2007-02-06 2015-02-12 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US20150224083A1 (en) * 2006-09-07 2015-08-13 Stemline Therapeutics, Inc. Cancer Therapy With Cantharidin And Cantharidin Analogs
WO2016014783A1 (en) * 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983661B1 (en) * 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
WO2016040877A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150224083A1 (en) * 2006-09-07 2015-08-13 Stemline Therapeutics, Inc. Cancer Therapy With Cantharidin And Cantharidin Analogs
US20150045373A1 (en) * 2007-02-06 2015-02-12 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2016014783A1 (en) * 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes

Also Published As

Publication number Publication date
JP6964593B2 (ja) 2021-11-10
US20220184066A1 (en) 2022-06-16
CA3051828A1 (en) 2017-08-03
WO2017132445A8 (en) 2018-12-20
EP3407887A4 (en) 2019-09-25
EP3407887B1 (en) 2021-09-01
US20190111053A1 (en) 2019-04-18
US20220323433A2 (en) 2022-10-13
JP2019507134A (ja) 2019-03-14
WO2017132445A1 (en) 2017-08-03
EP3407887A1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
US11337983B2 (en) Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
Roti Roti et al. Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice
CN109475543A (zh) 用磷酸酶抑制剂治疗骨髓发育不良综合征的临床方案
CN104918619B (zh) 稳定的肠胃外dnj组合物
CN111840561B (zh) S100a9抑制剂在制备治疗胰腺炎的药物中的应用
Shiraki et al. Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis
CN110724203A (zh) 一种促进tfeb核转位的短肽及基于其的线性短肽和其减轻脑缺血损伤的应用
CN120112294A (zh) 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法
Lozano et al. Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status
Soler-Agesta et al. Cancer cell-selective induction of mitochondrial stress and immunogenic cell death by PT-112 in human prostate cell lines
US12558367B2 (en) Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
Agustina et al. Side effects of methotrexate for psoriasis therapy
TW202034955A (zh) 使用免疫調節治療癌症之新穎方法
Rifkin et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma
Kondziolka et al. Neuronal transplantation for motor stroke: from the laboratory to the clinic
Abraham et al. Warfarin Induced Abnormal Uterine Bleeding: A Case Report
Hu et al. Hemodynamic collapse and severe metabolic acidosis following propofol in the setting of undiagnosed mitochondrial dysfunction: a case report
Campone et al. Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors
TW202428261A (zh) 用於治療重症肌無力的組成物與方法
JP2024502336A (ja) がんを治療するための医薬組成物、その製造方法及び使用
HK40000014B (en) Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor
Papadopoulou et al. Investigational New Drug‐Directed Toxicology and Pharmacokinetic Study of 4‐[3‐(2‐Nitro‐1‐Imidazolyl)‐Propylamino]‐7‐Chloroquinoline Hydrochloride (NLCQ‐1, NSC 709257) in Beagle Dogs
CN120114424A (zh) 甘露糖在制备铂类化疗诱导的血小板减少症药物中的应用
CN118910231A (zh) 一种新型靶点parp9蛋白及其靶向小分子化合物异甘草苷与应用
AU2019390418A1 (en) Therapeutic methods and compositions for treating acute myeloid leukemia using devimistat

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190315